Loading stock analysis…
Evidence Synthesis
Last synthesized: 20 Oct 2026, 09:15
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence velocity
Rate-of-change signals for this ticker unlock with Pro — or view flagship demos TCS / RELIANCE.
Evidence Synthesis
MAPROIN experienced a significant 100% gross margin acceleration, up from 70.87%.
The company's marginal operating leverage decelerated, down from 147.28%. Meanwhile, the daily volume accelerated, up from 13760 shares. Additionally, the close price accelerated, up from 82.44 INR.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 100 % | 70.87 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 70.87 % | 147.28 | ▼ |
| PRICE_CHANGE_PERCENT | 1.989 % | — | - |
| DAILY_VOLUME | 21,953 shares | 13,760 | ▲ |
| CLOSE_PRICE | 84.08 INR | 82.44 | ▲ |
Cite this
Source: Samhati evidence synthesis for MAPROIN (2026-10-20). Observation: MAPROIN experienced a significant 100% gross margin acceleration, up from 70.87%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/maproin
Filing step-changes